| Drug ID: | Drug8 |
|---|---|
| Drug Name: | Amitriptyline |
| CID: | 2160 |
| DrugBank ID: | DB00321 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06261320 |
| Molecular Formula: | C20H23N |
| Molecular Weight: | 277.4 g/mol |
| Isomeric SMILES: | CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31 |
| Synonyms: | amitriptyline; 50-48-6; Amitriptylin; Damitriptyline; Triptanol; Flavyl; Seroten; Proheptadiene; Lantron; Triptisol |
| Phase 0: | 1 |
| Phase 1: | 7 |
| Phase 2: | 36 |
| Phase 3: | 27 |
| Phase 4: | 23 |
| Description: | Amitriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amitriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, amitriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amitriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use). |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt60 | 2160 | Amitriptyline | 59340 | HRH4 | Homo sapiens (human) | 11179435 | None |
| dt61 | 2160 | Amitriptyline | 4986 | OPRK1 | Homo sapiens (human) | 19828880 | None |
| dt62 | 2160 | Amitriptyline | 1133 | CHRM5 | Homo sapiens (human) | 7855217 | None |
| dt63 | 2160 | Amitriptyline | 3736 | KCNA1 | Homo sapiens (human) | 17456683 | None |
| dt64 | 2160 | Amitriptyline | 3751 | KCND2 | Homo sapiens (human) | 9781919 | None |
| dt65 | 2160 | Amitriptyline | 3752 | KCND3 | Homo sapiens (human) | 9781919 | None |
| dt66 | 2160 | Amitriptyline | 29595 | Htr2a | Rattus norvegicus (Norway rat) | 10379421 | Antagonist |
| dt67 | 2160 | Amitriptyline | 29595 | Htr2a | Rattus norvegicus (Norway rat) | 8876023 | Antagonist |
| dt68 | 2160 | Amitriptyline | 6608 | SMO | Homo sapiens (human) | Inhibitor | |
| dt69 | 2160 | Amitriptyline | 1129 | CHRM2 | Homo sapiens (human) | 8100134 | Antagonist |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06261320 | Mesotherapy Treatment of Irritable Bowel Syndrome | PHASE2 | ACTIVE_NOT_RECRUITING | Polyclinique de l'Europe | Inflammatory Bowel Diseases | DRUG: Mesotherapy with mesocaine, thiocolchicosid… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
The protective effect of amitriptyline on experimental colitis through inhibiti…
PMID: 39892990
Year: 2025
Relationship Type:
Treatment
Score: 9.5
Amitriptyline, a pleiotropic tricyclic antidepressant, possesses antioxidant and anti-inflammatory properties. Despite its diverse benefits, the spec…
Anti-inflammatory Effect of Amitriptyline on Ulcerative Colitis in Normal and R…
PMID: 28228811
Year: 2016
Relationship Type:
Treatment
Score: 9.3
Depressive disorders are more common among persons with chronic diseases such as inflammatory bowel disease and anti-inflammatory effect of some anti…
Antidepressants for inflammatory bowel disease? Multimodal effects of amitripty…
PMID: 39892208
Year: 2025
Relationship Type:
Association
Score: 6.5
Anti-inflammatory effect of amitriptyline in a rat model of acetic acid-induced…
PMID: 33336463
Year: 2021
Relationship Type:
Treatment
Score: 6.5
HPS1, a BLOC-3 subunit that acts as a guanine nucleotide exchange factor of Rab32/38, may play a role in the removal of VAMP7 during the maturation …